Background
==========

Radiation therapy is a well-established treatment modality for clinically localized prostate cancer. Late radiation proctitis occurs at a frequency of 5--20% when radiotherapy is delivered with conventional radiation therapy for localized prostate cancer \[[@B1]\]. Patients with radiation-induced proctopathy describe symptoms of rectal pain, bowel frequency/urgency and rectal bleeding. These symptoms occur months to years after treatment (average 8--12 months), with the large majority of patients reporting symptoms within two years following pelvic radiation therapy \[[@B2],[@B3]\]. Patient characteristics such as a history of hemorrhoids, inflammatory bowel disease \[[@B4]\] or anticoagulation therapy \[[@B5]\] may increase an individual patient's risk for clinically significant proctopathy. Endoscopic findings in patients with clinical proctopathy include telangiectasia, congested mucosa, and ulcers. Rectal bleeding from neovascular telangiectasias is observed in 20-88% of patients receiving conventionally fractionated radiation therapy \[[@B6]\]. These rectal complications are the principle dose-limiting toxicities of radiotherapy. Several trials have demonstrated an improved biochemical failure-free survival with dose-escalation, but the increased rates of rectal toxicities are a potential barrier to the use of escalated doses \[[@B7]-[@B9]\].

The risk of proctitis and rectal bleeding appeared to be dependent upon both the total radiation dose and the volume of the rectum in the high dose area \[[@B10]\]. Treatment-related factors such as prostate motion and radiation schedules can contribute substantially to the severity of rectal toxicities. The prostate gland has been shown to move both interfractionally and intrafractionally during the delivery of external-beam radiotherapy \[[@B11]\]. As a result, a 0.5-1.5 cm margin is usually added to the clinical target volume (CTV) in generating the planning treatment volume (PTV) to account for this motion with conventional radiotherapy or intensity-modulated radiotherapy (IMRT). The need for such margins limits the ability to escalate dose to the prostate and spare normal tissues.

The optimal radiation schedule for the curative treatment of prostate cancer remains unknown. Recent data suggest that large radiation fraction sizes are radiobiologically favorable over lower fraction sizes in prostate cancer \[[@B12]-[@B14]\]. The α/β for prostate cancer may be as low as 1.5 Gy, \[[@B14]\] as opposed to values of 6--8 Gy reported for other adenocarcinomas \[[@B12]\]. If the α/β for prostate adenocarcinoma is less than the value of 3 Gy that is generally accepted for late rectal complications, the linear-quadratic model predicts a greater therapeutic gain for hypofractionated radiotherapy over conventionally fractionated treatment regimens. High dose-rate (HDR) brachytherapy using 6--9.5 Gy per fraction has been shown to be safe and effective in the treatment of localized prostate cancer \[[@B15]-[@B17]\]. The use of large fraction sizes in SBRT offers the potential radiobiologic benefits of hypofractionation with the minimal invasiveness of an external-beam treatment modality.

Stereotactic body radiation therapy (SBRT) offers to minimize radiation-associated rectal toxicity by reducing the volume of rectum receiving high radiation doses. The CyberKnife robotic radiosurgical system uses image guidance to track implanted fiducials to account for intrafraction prostatic motion \[[@B18]\]. This decreases the uncertainty of the location of the prostate and allows treatment to be delivered with a smaller CTV to PTV expansion, which reduces the doses delivered to the rectum. Early results from our center \[[@B19]\] and others \[[@B20]-[@B22]\] suggest a similar efficacy as alternative radiation modalities with low rates of late Grade ≥2 rectal toxicity (\< 10%). The goal of this study is to report the endoscopic findings following SBRT for clinically localized prostate cancer and correlate these outcomes with clinical rectal toxicity and quality of life.

Methods
=======

Patients treated at our institution with SBRT for clinically localized prostate cancer who underwent at least one post-treatment rectal endoscopy were identified and included in this retrospective review. Clinical stage was defined according to the 6^th^ edition of the American Joint Committee on Cancer criteria. Risk groups were defined using the National Comprehensive Cancer Network (NCCN) criteria. Institutional review board approval was obtained for this review.

SBRT was delivered using the CyberKnife robotic radiosurgical system. The fiducial placement and CT/MRI simulation procedures have been previously described in Lei *et al*. \[[@B23]\]. The clinical target volume (CTV) was defined as the prostatic capsule and proximal seminal vesicles (SV) up to the point that the SVs split, and included gross extracapsular extension or SV involvement seen on MRI. The expansion from the CTV to the planning target volume (PTV) was 5 mm in all directions except 3 mm posteriorly into the rectum. Fiducial-based tracking was used to account for intrafraction and interfraction prostate motion. Treatment planning was performed using Multiplan (Accuray Inc., Sunnyvale, CA). Patients with low-risk prostate cancer and select patients with intermediate-risk cancer were treated with 35 or 36.25 Gy of radiotherapy delivered in 5 fractions of 7--7.25 Gy each to the PTV \[[@B21],[@B24]\]. Patients with high-risk prostate cancer and most patients with intermediate-risk cancer were treated with 19.5 Gy of radiotherapy delivered in 3 fractions of 6.5 Gy each as a boost, followed by 45--50.4 Gy of intensity-modulated radiotherapy (IMRT) delivered in 1.8 Gy daily fractions \[[@B25]\]. The dose constraints to the rectum for SBRT have been previously described \[[@B24],[@B25]\]. An example of the dose distributions from an SBRT monotherapy plan is shown in Figure [1](#F1){ref-type="fig"}. Patients were placed on a low-residual diet and given enemas prior to simulation and treatment delivery to maximize the potential distance between the prostate and the rectal wall and minimize intrafraction prostate motion.

![**Treatment planning scan.** Axial **(A)** and sagittal **(B)** computed tomography images the prostate GTV (red line), bladder (orange line) and rectum (yellow demonstrating line). Isodose lines shown as follows: 100% of the prescription dose (lavender line); 90% of the prescription dose (yellow line); 75% of the prescription dose (green line); 50% of the prescription dose (brown line).](1748-717X-8-197-1){#F1}

Endoscopic proctopathy was graded and scored using the Vienna Rectoscopy Score (VRS) \[[@B26]\]. For VRS telangiectasia grading, a single telangiectasia is Grade 1, multiple non-confluent telangiectasia Grade 2, and multiple confluent telangiectasia Grade 3. For VRS congested mucosa grading, focal reddening of the mucosa combined with edematous mucosa is Grade 1, diffuse non-confluent reddening of the mucosa combined with edematous mucosa Grade 2, and diffuse confluent reddening of the mucosa combined with edematous mucosa Grade 3. If a patient had more than 1 endoscopy in the follow-up period, the worst endoscopic findings seen between all studies were recorded.

Clinical rectal toxicities were prospectively graded at each visit via CTCAE v.4. Clinical acute toxicities were defined as an increase of symptoms over the patient's pre-treatment baseline at any follow up visit prior to or at 6 months and late toxicities were defined as those that occur after 6 months. The toxicities analyzed were bowel frequency/urgency, rectal pain and rectal bleeding. At each follow-up visit, toxicity events were scored independently for each of the different toxicity types and the highest GI toxicity was determined for each patient. Quality of life (QOL) was assessed via the bowel domain of the Expanded Prostate Cancer Index (EPIC)-26 questionnaire prior to treatment and at scheduled follow-up visits after completion of radiotherapy \[[@B27]\]. The symptoms assessed included bowel urgency, bowel frequency, rectal incontinence, rectal bleeding, and rectal pain. As part of our institutional practice, if patients were unable to return to our institution for follow-up, QOL questionnaires were mailed out at the time points where the patient would normally have been seen, and the clinic notes from their follow-up visits with local physicians were obtained to assess for clinical toxicity.

The Wilcoxon signed-rank test was used to compare follow-up QOL scores to baseline scores. Decreases in the mean QOL scores at follow-up were considered clinically significant if they were worse by the minimally important difference (MID), which was defined as ½ of the baseline standard deviation (SD) \[[@B28]\]. All tests were two-tailed, and a value of *p* \< 0.05 was considered significant. SAS® version 9.2 was used to perform the statistical analyses.

Results
=======

Overall, we treated 365 patients with SBRT monotherapy and 120 patients with a SBRT boost and IMRT between January 2008 and May 2011. Fifty-one of these patients fit the inclusion criteria for this study, and their characteristics are described in Table [1](#T1){ref-type="table"}. The median interval from completion of SBRT to endoscopy was 13 months. The median clinical follow-up was 23 months. Two out of the 51 patients had 2 colonoscopies after SBRT.

###### 

Patient characteristics (n = 51)

  **Characteristic**                                                      **Median (range)**
  ----------------------------------------------------------------------- --------------------
  Age                                                                     67 (range 52--83)
  Length of clinical follow-up (months)                                   23 (range 8--47)
  Time after radiotherapy of the last post-treatment endoscopy (months)   13 (range 1--35)
  **Characteristic**                                                      **Number (%)**
  Ethnicity                                                                
   Caucasian                                                              30 (59%)
   African-America                                                        20 (39%)
   Other                                                                  1 (2%)
  Pre-SBRT use of anticoagulation therapy                                 11 (22%)
  Pre-SBRT hemorrhoids                                                    4 (8%)
  Radiotherapy                                                             
   SBRT monotherapy                                                       35 (69%)
   SBRT boost                                                             16 (31%)
  Androgen deprivation therapy                                             
   No                                                                     35 (69%)
   Yes                                                                    16 (31%)
  NCCN risk category                                                       
   Low                                                                    14 (27%)
   Intermediate                                                           28 (55%)
   High                                                                   9 (18%)
  Gleason score                                                            
   6                                                                      18 (35%)
   7                                                                      24 (47%)
   8                                                                      4 (8%)
   9                                                                      5 (10%)
  T stage                                                                  
   1c                                                                     28 (55%)
   2a                                                                     10 (20%)
   2b                                                                     8 (16%)
   2c                                                                     5 (10%)
  PSA                                                                      
   ≤ 10 ng/mL                                                             41 (80%)
   \> 10 ng/mL                                                            10 (20%)

A total of 16 (31%) patients reported rectal bleeding after SBRT, with 12 (24%) patients reporting acute bleeding and 10 patients (20%) reporting late bleeding. The highest rate of rectal bleeding occurred within 1 month post radiation treatment with 10 patients admitting to either Grade 1 or Grade 2 rectal bleeding. Six of these 10 patients experienced complete symptomatic resolution of these acute bleeds by the subsequent follow-up visit at 3 months. Grade 2 rectal bleeding was observed by only one patient who required minor cauterization secondary to a focal area of bleeding telangiectasias. Four of the 16 patients presenting with rectal bleeding (acute or late) had evidence of hemorrhoids without telangiectasias on endoscopy (see below). Overall, Grade 2 acute and late clinical rectal toxicities were observed in 10 (20%) and 3(6%) of patients, respectively. The majority of the toxicities were observed at one specific follow-up appointment and did not persist on subsequent follow-ups. There were no Grade 3 or higher acute or late clinical rectal toxicities.

On endoscopy, telangiectasias were found in 10 (20%) patients: 6 were treated with SBRT monotherapy and 4 where treated with SBRT as a boost. Nine of the 10 patients were observed to have non-confluent telangiectasias (VRS Grade 2) (Figure [2](#F2){ref-type="fig"}), and one was observed to have a single telangiectasia (VRS Grade 1). No patient had circumferential telangiectasia. Twelve patients (24%) had evidence of rectal mucositis on endoscopy, 11 patients (22%) with VRS Grade 1 and 1 patient (2%) with VRS Grade 2. No patients had a VRS grade for mucositis or telangiectasia of 3 or higher. No rectal ulcerations, strictures, or fistulas were observed. Of the 10 patients with late rectal bleeding, 3 had evidence of both telangiectasias and mucositis on endoscopy, 1 had telangiectasias without mucositis, and 1 had mucositis without telangiectasias.

![Example of multiple non-confluent telangiectasia (VRS Grade 2) on endoscopy.](1748-717X-8-197-2){#F2}

Twenty patients (39%) were noted to have hemorrhoids on endoscopy, although only 1 of these patients had complained of clinical symptoms of hemorrhoids on follow-up. Three additional patients had clinical symptoms of hemorrhoids but had no hemorrhoids seen during the time of endoscopy.

Mean EPIC bowel scores decreased from a baseline value of 96.9 to 82.3 at 1-month (*p* \< 0.001). These values subsequently improved, but were still lower compared to baseline values with 90.2 at 12-months (*p* \< 0.001) and 91.0 at 24-months (*p =* 0.01) post-SBRT. Figure [3](#F3){ref-type="fig"} illustrates the change of EPIC bowel QOL over subsequent follow-up.

![**Changes in EPIC bowel QOL post-SBRT as a function of time.** Mean EPIC bowel score for all patients reporting at the specified time points at baseline and in follow-up. The numbers represent the number of patients answering the questionnaire at that time point. The dashed ½ SD lines represent the clinical minimally important difference.](1748-717X-8-197-3){#F3}

Discussion
==========

Stereotactic body radiation therapy (SBRT) offers to minimize radiation-associated rectal toxicity by reducing the volume of rectum receiving high radiation doses. The low rate of late Grade ≥ 2 rectal toxicity seen in this study is consistent with the results from a prior review by our institution \[[@B19]\] and results from other institutions, \[[@B20]-[@B22]\] which all report a rate of late Grade ≥ 2 rectal toxicity of \< 10%. The lack of acute or late Grade 3 toxicity in these cohorts is particularly encouraging. Endoscopy is the gold standard for assessing rectal mucosal injury following radiation therapy. Our study is the first to examine endoscopic outcomes after prostate SBRT.

Since many of the patients in our study had an endoscopy to evaluate rectal symptoms, the study population is skewed towards patients who have more rectal complaints. However, even in this select group of patients, the rate of telangiectasias of 20% is lower than the rate of 32%-88% reported in prospective studies that have looked at endoscopic outcomes after 3D-CRT or IMRT \[[@B6],[@B26],[@B29]-[@B32]\]. In addition, no diffuse/confluent (VRS Grade 3) telangiectasias were seen in our patients, while a rate of 5%-25% is reported in the other studies. Based on our results and the results of others, we do not believe that intrarectal amifostine is necessary during prostate SBRT as others have reported \[[@B20]\].

In this select patient population, the overall incidence of post-treatment bleeds is 31%. However, only half of the patients who had telangiectasia on our study had symptomatic rectal bleeding. Additionally, 25% of our patients who reported rectal bleeding had hemorrhoids without evidence of telangiectasias on endoscopy. Together, this suggests that there could be alternative causes for the post-treatment bleeding seen in SBRT-treated patients aside from late post-radiotherapy telangiectasia. These causes could potentially include acute anal irritation or exacerbation of hemorrhoids.

Despite studying a patient population weighted towards those with rectal complaints, the pattern seen in the mean rectal QOL after SBRT in our study is similar to the pattern seen after conventionally fractionated radiotherapy or brachytherapy. The mean QOL score is at its lowest 1 or 2 months after treatment, but improves slowly thereafter to near baseline by 1--2 years after treatment.

Our study is limited by the retrospective nature of the analysis. Another limitation of this study is that the number of patients is relatively small, hampering our ability to perform an analysis of patient-specific and treatment-related factors that can affect rectal toxicity. In addition, the median follow up in this group of patients is relatively short, and additional clinical or endoscopic toxicities could potentially be seen with longer follow up.

Conclusions
===========

The treatment of prostate cancer with SBRT delivered using the CyberKnife system to doses of 35--36.25 Gy in 5 fractions or 19.5 Gy in 3 fractions with 45--50.4 Gy IMRT has a low rate of Grade \> 2 or higher toxicity. No rectal strictures, fistulas, ulcers, or perforations were observed. Prospective trials examining the endoscopic outcomes following SBRT for prostate cancer are needed for confirmation of the findings of this study.
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